George Nacos
Family Medicine · Washington, IANPI 1235159716
Payments from drug & device makers
Across 151 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$685
- AstraZeneca$358
- Pfizer$214
- Amgen$204
- Astellas Pharma US Inc$125
- AbbVie$106
- plus $527 from 13 others
What the payments were for
- Food & beverage$2,12696%
- Education$934%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 41 | $685 |
| AstraZeneca | 14 | $358 |
| Pfizer | 32 | $214 |
| Amgen | 14 | $204 |
| Astellas Pharma US Inc | 5 | $125 |
| AbbVie(2 entities) | 7 | $106 |
| Johnson & Johnson | 5 | $80 |
| Novartis | 4 | $68 |
| GSK | 5 | $62 |
| Novo Nordisk | 4 | $54 |
| Regeneron Healthcare Solutions, Inc. | 4 | $51 |
| Ironshore Pharmaceuticals Inc. | 4 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $38 |
| Teva Pharmaceuticals USA, Inc. | 3 | $36 |
| Boehringer Ingelheim | 2 | $31 |
| Merck | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,220 in reported general payments places this provider in the 85th percentile of 1,357 family medicine providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 234 | $179,214 |
| MounjaroTirzepatide | 128 | $131,518 |
| OzempicSemaglutide | 92 | $97,771 |
| XareltoRivaroxaban | 88 | $83,768 |
| CreonLipase/Protease/Amylase | 34 | $49,053 |
| Tresiba Flextouch U-200Insulin Degludec | 59 | $35,884 |
| Tresiba Flextouch U-100Insulin Degludec | 54 | $34,982 |
| JardianceEmpagliflozin | 42 | $30,303 |
| MyrbetriqMirabegron | 58 | $30,064 |
| GemtesaVibegron | 42 | $26,378 |
| EntrestoSacubitril/Valsartan | 26 | $26,004 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 33 | $25,609 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 29 | $23,247 |
| ProliaDenosumab | 12 | $21,246 |
| Repatha SureclickEvolocumab | 31 | $18,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $214 | $179,214234 claims |
| Novo NordiskOzempic | $54 | $97,77192 claims |
| Johnson & JohnsonXarelto | $80 | $83,76888 claims |
| AbbVieCreon, Linzess | $106 | $56,33048 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta | $31 | $47,42774 claims |
| Astellas Pharma US IncMyrbetriq | $125 | $30,06458 claims |
| NovartisEntresto | $68 | $26,00426 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $14 | $25,60933 claims |
| GSKIncruse Ellipta, Breo Ellipta, Anoro Ellipta | $62 | $23,86060 claims |
| AmgenProlia | $204 | $21,24612 claims |
| AstraZenecaFarxiga | $358 | $17,09415 claims |
| MerckJanuvia | $16 | $10,39033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Washington
- Nicholas GoetschWaterloo$4.1M
- James PoockWaterloo$1.5M
- Jennifer KayCouncil Bluffs$613K
- Nicholas BechtoldSioux City$584K
- Kirk PetersonHuxley$576K
- Stephen HarrisonClinton$249K
- Sharon SteenBelle Plaine$241K
- Carlos Alarcon SchroderJohnston$237K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.